Acasti Pharma Total Current Liabilities 2014-2024 | ACST

Acasti Pharma total current liabilities from 2014 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Acasti Pharma Annual Total Current Liabilities
(Millions of US $)
2024 $2
2023 $3
2022 $3
2021 $2
2020 $7
2019 $14
2018 $5
2017 $2
2016 $1
2015 $1
2015 $
2014 $1
2014 $
2013 $2
2013 $
Acasti Pharma Quarterly Total Current Liabilities
(Millions of US $)
2024-06-30 $3
2024-03-31 $2
2023-12-31 $2
2023-09-30 $1
2023-06-30 $2
2023-03-31 $3
2022-12-31 $3
2022-09-30 $4
2022-06-30 $4
2022-03-31 $3
2021-12-31 $3
2021-09-30 $4
2021-06-30 $2
2021-03-31 $2
2020-12-31 $2
2020-09-30 $4
2020-06-30 $6
2020-03-31 $7
2019-12-31 $11
2019-09-30 $12
2019-06-30 $13
2019-03-31 $14
2018-12-31 $10
2018-09-30 $10
2018-06-30 $8
2018-03-31 $5
2017-12-31 $4
2017-09-30 $3
2017-06-30 $1
2017-02-28 $2
2016-11-30 $1
2016-08-31 $1
2016-05-31 $1
2016-03-31 $1
2016-02-29
2015-12-31 $1
2015-09-30 $1
2015-06-30 $2
2015-03-31 $1
2014-12-31 $2
2014-09-30 $2
2014-06-30 $2
2014-03-31 $1
2014-02-28
2013-12-31 $5
2013-09-30 $4
2013-06-30 $3
2013-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.028B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.120B 6.83
Dr Reddy's Laboratories (RDY) India $13.079B 19.59
BridgeBio Pharma (BBIO) United States $5.045B 0.00
Bausch Health Cos (BHC) Canada $2.956B 2.23
Amphastar Pharmaceuticals (AMPH) United States $2.438B 13.65
Supernus Pharmaceuticals (SUPN) United States $1.771B 357.00
Taysha Gene Therapies (TSHA) United States $0.449B 73.00
Personalis (PSNL) United States $0.315B 0.00
Assembly Biosciences (ASMB) United States $0.117B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00